

CONTACT

040 6761 1600 / 6761 1700  
neuland@neulandlabs.com  
neulandlabs.com

June 28, 2025

To

**BSE Limited**

Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal  
Street, Mumbai – 400 001

**The National Stock Exchange of India Ltd**

Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref: Our letter dated May 2, 2025 on United States Food and Drug Administration (U.S.FDA) inspection at our Unit 2 manufacturing facility, located at Pashamylaram village, Sangareddy District**

We refer to our letter dated May 2, 2025 and would like to inform that U.S.FDA has issued an Establishment Inspection Report (EIR) against the inspection conducted at our Unit 2 manufacturing facility, located at Pashamylaram village, Sangareddy District, from April 28, 2025 to May 2, 2025.

The U.S.FDA has concluded that this inspection is “closed”.

This is for your information and records.

Thanking you

Yours Sincerely,

For **Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**